vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Richmond Mutual Bancorporation, Inc. (RMBI). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $13.1M, roughly 1.4× Richmond Mutual Bancorporation, Inc.). Richmond Mutual Bancorporation, Inc. runs the higher net margin — 26.1% vs -0.8%, a 26.9% gap on every dollar of revenue. On growth, Richmond Mutual Bancorporation, Inc. posted the faster year-over-year revenue change (18.1% vs -25.7%). Richmond Mutual Bancorporation, Inc. produced more free cash flow last quarter ($14.6M vs $-15.8M). Over the past eight quarters, Richmond Mutual Bancorporation, Inc.'s revenue compounded faster (9.1% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Richmond Mutual Bancorporation, Inc. is a U.S.-based bank holding company operating primarily in Indiana. It offers a full range of personal and commercial banking solutions including deposit accounts, mortgage loans, small business lending, and wealth management services, serving local retail consumers and small-to-medium enterprise clients via its regional branch network.
CTMX vs RMBI — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $13.1M |
| Net Profit | $-154.0K | $3.4M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | — |
| Net Margin | -0.8% | 26.1% |
| Revenue YoY | -25.7% | 18.1% |
| Net Profit YoY | 97.6% | 37.7% |
| EPS (diluted) | — | $0.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $13.1M | ||
| Q3 25 | — | $12.6M | ||
| Q2 25 | $18.7M | $11.8M | ||
| Q1 25 | $50.9M | $11.4M | ||
| Q4 24 | $38.1M | $11.1M | ||
| Q3 24 | $33.4M | $10.8M | ||
| Q2 24 | $25.1M | $10.7M | ||
| Q1 24 | $41.5M | $11.0M |
| Q4 25 | — | $3.4M | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | $-154.0K | $2.6M | ||
| Q1 25 | $23.5M | $2.0M | ||
| Q4 24 | $18.9M | $2.5M | ||
| Q3 24 | $5.7M | $2.5M | ||
| Q2 24 | $-6.5M | $2.1M | ||
| Q1 24 | $13.8M | $2.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -6.9% | — | ||
| Q1 25 | 44.4% | — | ||
| Q4 24 | 46.4% | — | ||
| Q3 24 | 12.3% | — | ||
| Q2 24 | -33.7% | — | ||
| Q1 24 | 28.1% | — |
| Q4 25 | — | 26.1% | ||
| Q3 25 | — | 28.6% | ||
| Q2 25 | -0.8% | 22.0% | ||
| Q1 25 | 46.2% | 17.2% | ||
| Q4 24 | 49.6% | 22.4% | ||
| Q3 24 | 17.2% | 23.0% | ||
| Q2 24 | -26.0% | 19.3% | ||
| Q1 24 | 33.3% | 21.6% |
| Q4 25 | — | $0.35 | ||
| Q3 25 | — | $0.36 | ||
| Q2 25 | — | $0.26 | ||
| Q1 25 | — | $0.20 | ||
| Q4 24 | — | $0.25 | ||
| Q3 24 | — | $0.24 | ||
| Q2 24 | — | $0.20 | ||
| Q1 24 | — | $0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $33.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $145.8M |
| Total Assets | $175.1M | $1.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $33.1M | ||
| Q3 25 | — | $34.3M | ||
| Q2 25 | $49.0M | $27.2M | ||
| Q1 25 | $47.6M | $27.0M | ||
| Q4 24 | $38.1M | $21.8M | ||
| Q3 24 | $40.6M | $19.6M | ||
| Q2 24 | $43.2M | $19.0M | ||
| Q1 24 | $36.2M | $20.3M |
| Q4 25 | — | $145.8M | ||
| Q3 25 | — | $140.0M | ||
| Q2 25 | $119.9M | $132.3M | ||
| Q1 25 | $25.0M | $130.9M | ||
| Q4 24 | $-456.0K | $132.9M | ||
| Q3 24 | $-23.5M | $140.0M | ||
| Q2 24 | $-31.2M | $131.1M | ||
| Q1 24 | $-31.7M | $132.4M |
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | $175.1M | $1.5B | ||
| Q1 25 | $98.5M | $1.5B | ||
| Q4 24 | $120.5M | $1.5B | ||
| Q3 24 | $139.0M | $1.5B | ||
| Q2 24 | $159.2M | $1.5B | ||
| Q1 24 | $184.7M | $1.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $16.0M |
| Free Cash FlowOCF − Capex | $-15.8M | $14.6M |
| FCF MarginFCF / Revenue | -84.6% | 111.9% |
| Capex IntensityCapex / Revenue | 0.1% | 10.4% |
| Cash ConversionOCF / Net Profit | — | 4.68× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $26.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $16.0M | ||
| Q3 25 | — | $6.3M | ||
| Q2 25 | $-15.8M | $4.8M | ||
| Q1 25 | $-21.0M | $2.2M | ||
| Q4 24 | $-19.9M | $14.8M | ||
| Q3 24 | $-20.7M | $2.9M | ||
| Q2 24 | $-19.5M | $2.9M | ||
| Q1 24 | $-26.0M | $2.2M |
| Q4 25 | — | $14.6M | ||
| Q3 25 | — | $5.8M | ||
| Q2 25 | $-15.8M | $4.2M | ||
| Q1 25 | $-21.2M | $2.1M | ||
| Q4 24 | $-20.0M | $14.3M | ||
| Q3 24 | $-20.7M | $2.8M | ||
| Q2 24 | $-19.6M | $2.8M | ||
| Q1 24 | $-26.2M | $2.0M |
| Q4 25 | — | 111.9% | ||
| Q3 25 | — | 46.2% | ||
| Q2 25 | -84.6% | 35.6% | ||
| Q1 25 | -41.6% | 18.4% | ||
| Q4 24 | -52.5% | 129.3% | ||
| Q3 24 | -62.1% | 25.7% | ||
| Q2 24 | -78.2% | 26.2% | ||
| Q1 24 | -63.1% | 18.7% |
| Q4 25 | — | 10.4% | ||
| Q3 25 | — | 3.7% | ||
| Q2 25 | 0.1% | 5.3% | ||
| Q1 25 | 0.2% | 0.7% | ||
| Q4 24 | 0.2% | 4.2% | ||
| Q3 24 | 0.1% | 1.1% | ||
| Q2 24 | 0.4% | 1.1% | ||
| Q1 24 | 0.3% | 1.1% |
| Q4 25 | — | 4.68× | ||
| Q3 25 | — | 1.75× | ||
| Q2 25 | — | 1.86× | ||
| Q1 25 | -0.89× | 1.11× | ||
| Q4 24 | -1.05× | 5.96× | ||
| Q3 24 | -3.61× | 1.17× | ||
| Q2 24 | — | 1.42× | ||
| Q1 24 | -1.89× | 0.91× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
RMBI
Segment breakdown not available.
